Acetoside
CAS 61276-17-3
Acetoside (CAS 61276-17-3) is a Phase 2 pharmaceutical compound with 7 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 22396.772 nM | 25 | - |
| - | Potency | 30028.340000000004 nM | 20 | - |
| - | MIC | 160.71428571428572 ug.mL-1 | 7 | - |
| - | EC50 | 2.8899999999999997 ug.mL-1 | 4 | - |
| - | IC50 | 16.1225 ug.mL-1 | 4 | - |
| - | EC50 | 11346.666666666666 nM | 3 | - |
| - | Ki | 16900 nM | 3 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPV3 TRPV3 |
Inhibition | 4.849999904632568 pIC50 | 31983608 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Acetoside used for in pharmaceutical contexts?
Acetoside (CAS 61276-17-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Acetoside?
No adverse-event association or SIDER side-effect rows are rendered for Acetoside in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Acetoside also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Verbascoside with EU status "permitted".
What clinical phase is Acetoside in?
Acetoside is rendered with ChEMBL max phase 2.